Beginning 23 March, the US Food and Drug Administration (FDA) is going to convert more than 100 medicines approved under new drug applications (NDAs) to biologics license applications (BLAs) because ...
In December 2020, the U.S. District Court for the District of Columbia issued a decision in Teva v. FDA, reviewing FDA’s definition of “protein” in connection with the agency’s determination that Teva ...
Teva Pharmaceutical Industries Ltd has lost a bid to force the U.S. Food and Drug Administration to regulate its blockbuster multiple sclerosis drug Copaxone as a biologic drug, which would have ...
Momenta Pharmaceuticals Inc. and partner Sandoz Inc. said the FDA accepted their abbreviated new drug application for M356, a generic version of peptide-based multiple sclerosis drug Copaxone ...
FDA is widely known to be considering the approval of a generic version of Teva Pharmaceutical’s (NYSE:TEVA) blockbuster drug for multiple sclerosis, Copaxone. The patents covering Copaxone for its ...
Copaxone (glatiramer) is a prescription drug that’s used in adults to treat certain types of multiple sclerosis and clinically isolated syndrome. Copaxone comes as a liquid solution that you’ll inject ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results